What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, and one of the busiest molecules in your body. It works as a shuttle that helps cells convert nutrients into usable energy, and it doubles as fuel for the enzymes that repair DNA and manage cellular stress. Every heartbeat, every thought, every repair job runs a NAD+ tab.
The observation that made it famous: NAD+ levels appear to decline with age across many tissues. That led to a simple, appealing hypothesis, that restoring NAD+ might support cellular health later in life. A decline is a clue, not proof, and the honest version of this article is the story of a field working to turn that clue into evidence.
How does it work?
NAD+ itself is absorbed poorly when swallowed, so most research and supplementation focuses on precursors, the building blocks the body converts into NAD+. The two most studied are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Supply the building blocks, the logic goes, and cells can maintain or rebuild their NAD+ pool.
Downstream, NAD+ supports mitochondrial energy production and feeds enzyme families with real jobs: sirtuins, involved in stress response and metabolic regulation, and PARPs, central to DNA repair. A 2023 review in Endocrine Reviews lays this biology out in detail, and it also states the open question honestly: whether raising NAD+ actually delivers the benefits the mechanism predicts.
Why it matters in regenerative medicine
Energy is upstream of everything. Fatigue, slow recovery, and poor stress tolerance are among the most common complaints in any wellness practice, and mitochondrial function sits underneath all of them. That is why NAD+ became a fixture of longevity and recovery protocols, from oral precursors to the IV NAD+ drips now offered in clinics everywhere: it targets the machinery every other therapy depends on.
It is also why the claims around it inflated faster than the data. The biology is genuinely central; the leap from central biology to reversed aging is the part the trials have not delivered.
What it is used for
In research, NAD+ precursors are being studied for healthy aging and metabolic health, insulin sensitivity and cardiometabolic markers, and increasingly for neurological conditions. In practice, NAD+ shows up as oral NMN or NR for daily support and as IV infusions in recovery, energy, and longevity protocols, often alongside other compounds.
What the controlled trials establish so far is specific: precursors reliably raise blood NAD+ levels and have been well tolerated over the periods studied. A 2023 multicentre randomized trial in 80 healthy middle-aged adults, at NMN doses up to 900mg daily, raised blood NAD+ across all dose groups with no safety issues, and reported improvement on a six-minute walking test.
What people notice in practice
What users commonly report, labeled honestly as experience rather than trial evidence, clusters around energy and clarity: steadier afternoons, better recovery from training and travel, sharper focus, with IV protocols producing the most vivid reports. Others take it for months and notice nothing they can point to. Both experiences are consistent with a molecule whose measurable effect, raising blood NAD+, is real, while the felt effect varies person to person.
The usual honest gap applies: almost nobody tracks bloodwork or function alongside their supplementation, so the experiences stay anecdotal while the trials grind toward answers.
The pros and the cons
What's promising
- The biology is well characterized and genuinely central to energy and repair.
- Precursors reliably raise blood NAD+ in controlled trials.
- Short-term safety signals are reassuring across the studied groups.
- Serious trials are now running, including a 410-person Phase 3 in early Parkinson's disease.
What's uncertain
- Trials have not yet shown a consistent anti-aging or disease-modifying benefit in people, a point the 2025 Nature Metabolism review states plainly.
- Raising a blood marker is not the same as improving a life; the outcome trials are still in progress.
- Study designs, durations, and endpoints vary widely, which muddies the pooled picture.
- Long-term human data does not exist yet.
Worth considering
- Supplement quality varies; precursor products are only as good as their manufacturing.
- Oral precursors and IV NAD+ have never been compared head to head in a trial.
- Expectations belong at the level of the evidence: supported biology, unproven outcomes.
- A clinician who knows your bloodwork and goals beats a headline about reversing aging.
Why the evidence lags the hype
Two structural reasons. Precursors like NMN and NR sell as supplements, and a molecule already on the shelf earns nobody the exclusive rights that fund large outcome trials. And the headline claim, slower aging, is close to the hardest endpoint in medicine to measure: it takes years, big cohorts, and endpoints regulators accept. So the market ran ahead on mechanism while the definitive trials are only now arriving. The Parkinson's and insulin-sensitivity studies below are what turning hype into knowledge actually looks like.
What the key studies tested
Our framing rule for evidence: a trial tests one compound, at one dose, in one population, on one endpoint. Where the evidence sits:
Preclinical & practice
The aging claims, and most IV and combination uses offered in clinics.
Early trials
Bioavailability and safety in healthy adults; insulin sensitivity in prediabetes.
Late-stage trials
NOPARK: 410 people with early Parkinson's, nicotinamide riboside vs placebo over 52 weeks.
Approved uses
None as a therapy. Precursors are sold as supplements, a lower bar.
And the studies that matter most:
- The 2023 randomized trial in 80 healthy middle-aged adults: NMN up to 900mg daily raised blood NAD+ at every dose, was well tolerated, and improved six-minute walking distance.
- The Washington University clamp study: NMN in postmenopausal women with prediabetes, measuring insulin sensitivity with the field's gold-standard method rather than a survey.
- NOPARK: the largest effort to date, a Phase 3 trial of nicotinamide riboside in early Parkinson's disease with a disease-severity score as the primary endpoint.
- The 2025 Nature Metabolism review: precursors reliably raise NAD+ markers, and clear, consistent clinical benefits are not yet demonstrated. That sentence is the current state of the field.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Why take precursors instead of NAD+ itself?
Oral NAD+ is absorbed poorly, so research and supplementation focus on the building blocks the body converts into NAD+, chiefly NMN and NR. Controlled trials show these reliably raise blood NAD+ levels, which settles the delivery question and leaves the more important one: what raising NAD+ actually changes.
Is IV NAD+ better than oral precursors?
Nobody knows, honestly. The two routes have never been compared head to head in a controlled trial. IV delivery bypasses absorption entirely, and infusion protocols are popular in practice, but the published trial evidence was built almost entirely on oral precursors. That is a gap, not a verdict in either direction.
Is NAD+ supplementation safe?
Within the studied windows, yes: the controlled trials of NMN and NR report good tolerability with no safety issues emerging, including at NMN doses up to 900mg daily. What does not exist is long-term human safety data, and supplement manufacturing quality varies, so sourcing matters.
Does NAD+ reverse aging?
No trial has shown that. What is established: NAD+ declines with age, precursors restore blood levels, and short-term use is well tolerated. What is not established: any consistent anti-aging or disease-modifying benefit in people. The current wave of larger trials, including the Parkinson's study, is designed to answer exactly that.
What to take away
If you remember five things from this article, make them these:
- NAD+ is genuinely central biology: the coenzyme behind cellular energy, DNA repair, and stress response.
- Precursors like NMN and NR reliably raise blood NAD+ in controlled trials and have been well tolerated.
- No trial has yet shown a consistent anti-aging or disease-modifying benefit; the outcome trials are running now.
- Oral versus IV has never been tested head to head; practice preference is ahead of the data.
- Fit it to your case with a clinician, with expectations set by the evidence rather than the headlines.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. NAD+ is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.